8 results about "Viral isolate" patented technology

The invention discloses a cat infectious peritonitis virus isolate and application thereof. The cat infectious peritonitis virus is separated from the peritoneal fluid of a 6-month-old female gradient silver cat, the preservation number of the cat infectious peritonitis virus is CGMCC (China General Microbiological Culture Collection Center) No.46420, and the name of the cat infectious peritonitis virus is SHAANXI-FIBV-II-2024. An animal model is successfully established by using the strain.

The application discloses a D type influenza virus isolate D / HY11 and application thereof in a mink infection model, and belongs to the field of biological medicines. The application takes the D type influenza virus isolate D / HY11 of an IDV northeast isolate as a research object, establishes a mink transmission model, evaluates the transmission dynamics characteristics of the strain among minks, identifies amino acid mutations possibly related to host adaptability through whole genome sequencing, analyzes the amino acid substitution on receptor affinity based on computer simulation of protein conformation and receptor molecule docking, explores the host adaptation evolution law of the virus in the transmission process, and provides an important scientific basis for early warning and prevention and control of a public health crisis possibly caused by the IDV.

This invention concerns immunogenic B cell epitopes of the RPO30 protein of the Lumpy Skin Disease virus isolate from East Java as vaccine candidates in the field of animal health. This invention relates to the identification, characterization, and utilization of immunogenic B cell epitopes derived from the RPO30 protein of the Lumpy Skin Disease virus isolate from East Java. The identified B cell epitopes were selected from the group consisting of SL, D, TSSYESTSSQ, and QGMGGYT, which have the ability to induce specific humoral immune responses against the Lumpy Skin Disease virus. These B cell epitopes can be chemically synthesized or recombinantly expressed and formulated with a veterinary acceptable carrier or pharmaceutical adjuvant to produce an epitope-based vaccine candidate. This invention provides an alternative vaccine candidate that is safer than live attenuated vaccines, has the potential to reduce post-vaccination side effects, and is more specific to local Indonesian isolates.This invention is expected to be used for the prevention of Lumpy Skin Disease in cattle and buffalo.

The present disclosure is directed to novel porcine sapoviruses (SaV) isolates, including SaV serially propagated in cell culture, all of which are useful in the preparation of immunogenic compositions and vaccines for treating and preventing disease in swine. The disclosure further provides characterization of pathogenicity and cross-protective immunity of contemporary porcine SaV isolates in weaned pigs, demonstrating that prior exposure to homologous strains provides greater protection against viral shedding than heterologous strains.

The present invention relates to the technical fields of molecular biology and immunological analysis, and specifically to a broad-spectrum monoclonal antibody capable of recognizing coxsackievirus A2, A4, and A5, and its use. The monoclonal antibody comprises a heavy chain complementary determining region (CDR1) as set forth in SEQ ID NO.9, a heavy chain complementary determining region (CDR2) as set forth in SEQ ID NO.10, a heavy chain complementary determining region (CDR3) as set forth in SEQ ID NO.11, and a light chain complementary determining region (CDR1) as set forth in SEQ ID NO.12, a light chain complementary determining region (CDR2) as set forth in SEQ ID NO.13, and a light chain complementary determining region (CDR3) as set forth in SEQ ID NO.14. The monoclonal antibody specifically binds to the N-terminal 15 amino acids of the structural protein VP1 of coxsackievirus A2, A4, and A5, and can be used for clinical patient sample testing, laboratory antibody identification of virus isolates, and quantitative detection of coxsackievirus A2, A4, and A5 antigens in production intermediates and products.

The application discloses an atypical swine pestivirus isolated strain suitable for cell culture and application thereof. The application isolates an APPV isolated strain suitable for cell culture from a dead piglet determined as APPV infection, and the microbial preservation number of the APPV isolated strain is CGMCC No. 45417. The APPV isolated strain can be continuously and stably passaged and proliferated in PK-15 cells, and the virus titer gradually increases during the passage. Virus neutralization test (VNT) shows that VNT based on the APPV isolated strain can effectively distinguish APPV antibody positive serum and negative serum. The APPV isolated strain provided by the application provides key materials for biological and pathogenicity research of APPV, development of vaccines and diagnostic reagents, and has important application prospects for diagnosis of diseases caused by APPV, improvement of infection monitoring system and control of diseases caused by APPV, and can also be used for preparing diagnostic or preventive and therapeutic detection reagents or vaccines for APPV infection.

The present invention relates to the fields of molecular biology and immunological analysis technology, and specifically to a monoclonal antibody capable of recognizing coxsackievirus A2 and A4 and its use. The monoclonal antibody comprises a heavy chain complementary determining region (CDR1) as set forth in SEQ ID NO.9, a heavy chain complementary determining region (CDR2) as set forth in SEQ ID NO.10, a heavy chain complementary determining region (CDR3) as set forth in SEQ ID NO.11, and a light chain complementary determining region (CDR1) as set forth in SEQ ID NO.12, a light chain complementary determining region (CDR2) as set forth in SEQ ID NO.13, and a light chain complementary determining region (CDR3) as set forth in SEQ ID NO.14. The monoclonal antibody specifically binds to the first 15 amino acids at the N-terminus of the structural protein VP1 of coxsackievirus A2 and A4, and can be used for clinical patient sample testing, laboratory antibody identification of virus isolates, and quantitative detection of coxsackievirus A2 and A4 antigens in production intermediates and products.

This invention concerns the RPO30 protein of an Indonesian isolate of Lumpy Skin Disease virus and its use in the development of an epitope-based vaccine in the field of animal health. This invention relates to the provision of the RPO30 protein or its immunogenic B cell epitope fragment derived from an Indonesian isolate of Lumpy Skin Disease virus as an active vaccine ingredient. The RPO30 protein or the immunogenic B cell epitope fragment is identified through genetic sequence analysis and immunogenicity prediction, then chemically synthesized or recombinantly expressed. The immunogenic B cell epitope fragment is then formulated with a veterinary acceptable carrier or pharmaceutical adjuvant to produce an epitope-based vaccine. This epitope-based vaccine is designed to induce a specific humoral immune response against Lumpy Skin Disease virus without the use of live virus.This invention provides an alternative for developing a safer vaccine, specific to local Indonesian isolates, and potentially reducing post-vaccination side effects. It is hoped that this invention can be used to prevent Lumpy Skin Disease in cattle and buffalo.